

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR MARKETING OF
CATEGORY 1 INNOVATIVE DRUG “TQ-B3101 CAPSULE”

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that application for marketing of Category 1 anti-tumor innovative drug “TQ-B3101 Capsule” developed by the Group has been submitted to and accepted by the National Medical Products Administration of the PRC. The indication for this application is non-small cell lung cancer which is positive for ROS1.

TQ-B3101 Capsule is a tyrosine kinase ROS1/ALK/c-Met small molecule inhibitor self-developed by the Group. TQ-B3101 can selectively inhibit the in vitro proliferation of ROS1-positive, ALK-positive and c-Met tumor cells, inducing the cell cycle arrest in G1 phase and inducing cell apoptosis. This will ultimately exert effective anti-tumor effects and improve the survival prognosis of patients with non-small cell lung cancer. Current clinical data showed that TQ-B3101 is apparently effective in the treatment of non-small cell lung cancer both in the short term and long term, and it has low eye toxicity and a good safety profile.

TQ-B3101 Capsule is another Category 1 innovative drug recently applied for marketing by the Group after TQ-B3139. The Group has continuously achieved breakthroughs on the research and development of innovative drugs, and our new drug pipeline has gradually entered the harvesting period.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 27 June 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.